Trial · NCT00446641

Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

NCT00446641, Phase 4, Completed, Asan Medical Center; results first posted 2010-01-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Overcome Biochemical Aspirin Resistance Through Cilostazol Combination. Trials, record NCT00446641. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00446641

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
NCT number: NCT00446641
Status: Completed
Phases: Phase 4
Enrollment: 244 participants, actual
Lead sponsor: Asan Medical Center
Conditions: Cerebral Infarction
Interventions: Cilostazol, placebo
First posted: 2007-03-13
Last updated: 2010-01-18
Results first posted: 2010-01-18

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Aspirin Resistance (ARU ≥ 550)	4 weeks after treatment	The number of patients with aspirin reaction units (ARUs) values ≥ 550 on the Ultra Rapid Platelet Function Assay-ASA among the recruited patients
Secondary	Aspirin Resistance (ARU ≥ 500)	4 weeks after reatment	The number of participants with ARUs values ≥500 on the Ultra Rapid Platelet Function Assay-ASA; ARUs values
Secondary	Bleeding Time (BT)	4 weeks after reatment	for evaluation of the extent of the bleeding time prolongation by additional cilostazol
Secondary	Fatal or Major Bleeding Complications;	events ocurred during study medication after randomization	Fatal or life-threatening bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood
Secondary	Any Bleeding Complications	events ocurred during study medication after randomization	any bleeding events causing medical attention
Secondary	Difference of Post-treatment ARU and Baseline ARU	baseline ARU measured at the randomization and post-treatment ARU measured at the 4weeks treatment with study medication	summation of change of ARU (posttreatment ARU - baseline ARU) of individual patients
Secondary	Post-treatment ARU	after 4 weeks treatment	mean of ARU value of individual participants after 4 weeks treatment

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Aspirin Resistance (ARU ≥ 550)	4 weeks after treatment	participants	NUMBER
SECONDARY	Aspirin Resistance (ARU ≥ 500)	4 weeks after reatment	participants	NUMBER
SECONDARY	Bleeding Time (BT)	4 weeks after reatment	seconds	MEAN
SECONDARY	Fatal or Major Bleeding Complications;	events ocurred during study medication after randomization	participants	NUMBER
SECONDARY	Any Bleeding Complications	events ocurred during study medication after randomization	participants	NUMBER
SECONDARY	Difference of Post-treatment ARU and Baseline ARU	baseline ARU measured at the randomization and post-treatment ARU measured at the 4weeks treatment with study medication	change of ARU measured	MEAN
SECONDARY	Post-treatment ARU	after 4 weeks treatment	ARU	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Aspirin Resistance (ARU ≥ 550)	Cilostazol	9		participants
Aspirin Resistance (ARU ≥ 550)	Placebo	11		participants
Aspirin Resistance (ARU ≥ 500)	Cilostazol	20		participants
Aspirin Resistance (ARU ≥ 500)	Placebo	28		participants
Bleeding Time (BT)	Cilostazol	113	Standard Deviation 38.5	seconds
Bleeding Time (BT)	Placebo	106	Standard Deviation 34.2	seconds
Fatal or Major Bleeding Complications;	Cilostazol	0		participants
Fatal or Major Bleeding Complications;	Placebo	0		participants
Any Bleeding Complications	Cilostazol	0		participants
Any Bleeding Complications	Placebo	0		participants

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Cilostazol	125
Overall Study	STARTED	Placebo	119
Overall Study	COMPLETED	Cilostazol	108
Overall Study	COMPLETED	Placebo	109
Overall Study	NOT COMPLETED	Cilostazol	17
Overall Study	NOT COMPLETED	Placebo	10

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	headache	Nervous system disorders	Cilostazol	7	125	7
other	headache	Nervous system disorders	Placebo	2	119	2

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Cilostazol
Total, all-cause mortality	Placebo
Total, other adverse events	Cilostazol	7	125
Total, other adverse events	Placebo	2	119
Total, serious adverse events	Cilostazol	0	125
Total, serious adverse events	Placebo	0	119

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Cilostazol vs Placebo: Aspirin Resistance (ARU ≥ 550)	Trial comparisons
Cilostazol vs Placebo: Aspirin Resistance (ARU ≥ 500)	Trial comparisons
Cilostazol vs Placebo: Any Bleeding Complications	Trial comparisons
Cilostazol vs Placebo: Fatal or Major Bleeding Complications;	Trial comparisons
Cilostazol vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00446641

GET https://conductscience.org/api/trials/v1/NCT00446641/registered

API reference For AI assistants